Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 * Predicted life expectancy of \>= 12 weeks * Previous surgery * Histologically or cytologically confirmed, measurable, locally advanced, unresectable or metastatic pancreatic adenocarcinoma * No prior therapy for pancreatic cancer * Adequate organ and marrow function * Absolute neutrophil count \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Total bilirubin \<= institutional upper limits of normal * AST (SGOT)/ALT(SGPT) \<= 2 x institutional upper limits of normal * Serum creatinine \<= 1.5 x upper limits of normal * Negative pregnancy test * Informed consent * Patient must agree not to smoke while on study Exclusion Criteria: * Significant history of cardiac disease unless the disease is well controlled * Active or uncontrolled infections or serious illness or medical conditions that could interfere with the patient's ongoing participation in study * History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent * History of smoking within the previous 14 days before enrollment or positive cotinine test at baseline * Pregnant or breast-feeding females * Symptomatic brain metastases that are not stable, that require steroids, that are potentially life-threatening, or that have required radiation within the last 14 days * History of allergic reactions attributed to compounds of similar chemical or biological composition to the study drugs